Cargando…

Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19

The emerging Coronavirus Disease 2019 (COVID-19) pandemic has posed a serious threat to the public health worldwide, demanding urgent vaccine provide. According to the virus feature as an RNA virus, a high rate of mutations imposes some vaccine design difficulties. Bioinformatics tools have been wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadat, Seyed Mehdi, Aghadadeghi, Mohammad Reza, Yousefi, Masoume, Khodaei, Arezoo, Sadat Larijani, Mona, Bahramali, Golnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902242/
https://www.ncbi.nlm.nih.gov/pubmed/33625681
http://dx.doi.org/10.1007/s12033-021-00303-0
_version_ 1783654521131499520
author Sadat, Seyed Mehdi
Aghadadeghi, Mohammad Reza
Yousefi, Masoume
Khodaei, Arezoo
Sadat Larijani, Mona
Bahramali, Golnaz
author_facet Sadat, Seyed Mehdi
Aghadadeghi, Mohammad Reza
Yousefi, Masoume
Khodaei, Arezoo
Sadat Larijani, Mona
Bahramali, Golnaz
author_sort Sadat, Seyed Mehdi
collection PubMed
description The emerging Coronavirus Disease 2019 (COVID-19) pandemic has posed a serious threat to the public health worldwide, demanding urgent vaccine provide. According to the virus feature as an RNA virus, a high rate of mutations imposes some vaccine design difficulties. Bioinformatics tools have been widely used to make advantage of conserved regions as well as immunogenicity. In this study, we aimed at immunoinformatic evaluation of SARS-CoV-2 proteins conservancy and immunogenicity to design a preventive vaccine candidate. Spike, Membrane and Nucleocapsid amino acid sequences were obtained, and four possible fusion proteins were assessed and compared in terms of structural features and immunogenicity, and population coverage. MHC-I and MHC-II T-cell epitopes, the linear and conformational B-cell epitopes were evaluated. Among the predicted models, the truncated form of Spike in fusion with M and N protein applying AAY linker has high rate of MHC-I and MCH-II epitopes with high antigenicity and acceptable population coverage of 82.95% in Iran and 92.51% in Europe. The in silico study provided truncated Spike-M-N SARS-CoV-2 as a potential preventive vaccine candidate for further in vivo evaluation.
format Online
Article
Text
id pubmed-7902242
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-79022422021-02-24 Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19 Sadat, Seyed Mehdi Aghadadeghi, Mohammad Reza Yousefi, Masoume Khodaei, Arezoo Sadat Larijani, Mona Bahramali, Golnaz Mol Biotechnol Original Paper The emerging Coronavirus Disease 2019 (COVID-19) pandemic has posed a serious threat to the public health worldwide, demanding urgent vaccine provide. According to the virus feature as an RNA virus, a high rate of mutations imposes some vaccine design difficulties. Bioinformatics tools have been widely used to make advantage of conserved regions as well as immunogenicity. In this study, we aimed at immunoinformatic evaluation of SARS-CoV-2 proteins conservancy and immunogenicity to design a preventive vaccine candidate. Spike, Membrane and Nucleocapsid amino acid sequences were obtained, and four possible fusion proteins were assessed and compared in terms of structural features and immunogenicity, and population coverage. MHC-I and MHC-II T-cell epitopes, the linear and conformational B-cell epitopes were evaluated. Among the predicted models, the truncated form of Spike in fusion with M and N protein applying AAY linker has high rate of MHC-I and MCH-II epitopes with high antigenicity and acceptable population coverage of 82.95% in Iran and 92.51% in Europe. The in silico study provided truncated Spike-M-N SARS-CoV-2 as a potential preventive vaccine candidate for further in vivo evaluation. Springer US 2021-02-24 2021 /pmc/articles/PMC7902242/ /pubmed/33625681 http://dx.doi.org/10.1007/s12033-021-00303-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Sadat, Seyed Mehdi
Aghadadeghi, Mohammad Reza
Yousefi, Masoume
Khodaei, Arezoo
Sadat Larijani, Mona
Bahramali, Golnaz
Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19
title Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19
title_full Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19
title_fullStr Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19
title_full_unstemmed Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19
title_short Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19
title_sort bioinformatics analysis of sars-cov-2 to approach an effective vaccine candidate against covid-19
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902242/
https://www.ncbi.nlm.nih.gov/pubmed/33625681
http://dx.doi.org/10.1007/s12033-021-00303-0
work_keys_str_mv AT sadatseyedmehdi bioinformaticsanalysisofsarscov2toapproachaneffectivevaccinecandidateagainstcovid19
AT aghadadeghimohammadreza bioinformaticsanalysisofsarscov2toapproachaneffectivevaccinecandidateagainstcovid19
AT yousefimasoume bioinformaticsanalysisofsarscov2toapproachaneffectivevaccinecandidateagainstcovid19
AT khodaeiarezoo bioinformaticsanalysisofsarscov2toapproachaneffectivevaccinecandidateagainstcovid19
AT sadatlarijanimona bioinformaticsanalysisofsarscov2toapproachaneffectivevaccinecandidateagainstcovid19
AT bahramaligolnaz bioinformaticsanalysisofsarscov2toapproachaneffectivevaccinecandidateagainstcovid19